PETV

PetVivo Holdings, Inc. Common Stock

PETV

Market cap $16.3M

Delisted

PETV was delisted on the 8th of April, 2024.

Back to rankings

About: PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.

Employees: 25

Healthcare Medical Instruments & Supplies

Financial journalist opinion

PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript

PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2026 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Garry N. Lowenthal - Chief Financial Officer John Lai - CEO, President & Director John F.

PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript

PetVivo Reports Fiscal Q1 2026 Results

MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTC ID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted.

PetVivo Reports Fiscal Q1 2026 Results

PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET

MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call.

PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET

PetVivo Holdings Inc. to Trade on OTCQX Best Market

MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, such as Spryng® with OsteoCushion® Technology and PrecisePRP®, today announced that the Company has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market.

PetVivo Holdings Inc. to Trade on OTCQX Best Market

PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript

PetVivo Holdings, Inc. (OTCPK:PETV) Q4 2025 Earnings Conference Call June 30, 2025 5:00 PM ET Company Participants Garry N. Lowenthal - Chief Financial Officer John Lai - CEO, President & Director John F.

PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript

PetVivo Reports Fiscal 2025 Results

MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change.

PetVivo Reports Fiscal 2025 Results

PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET

MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Monday, June 30, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2025. The financial results will be issued in a press release prior to the call.

PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET

PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently received One Million Dollars ($1,000,000) pursuant to the full exercise of the remaining Shares offered in a purchase option (“Purchase Option”) granted to the investor as part of an offering to receive Five Million Dollars ($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock (“Shares”) (the “Offering”); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock. The Company has previously received an aggregate total of Four Million Dollars ($4,000,000) of the Offering prior to the current Purchase Option exercise. The exercise of the remaining One Million Dollars ($1,000,000) of the Purchase Option completes the issuance of all Shares allowed and thereby closes the Purchase Option of the Offering.

PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

PETVIVO HOLDINGS, INC. ANNOUNCES INVESTOR EXERCISE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

MINNEAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently received Three Million Dollars ($3,000,000) pursuant to a partial exercise of a purchase option (“Purchase Option”) granted to the investor as part of an offering to receive Five Million Dollars ($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock (“Shares”) (the “Offering”); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock. The Company has previously received an aggregate total of One Million Dollars ($1,000,000) of the Offering prior to the current Purchase Option exercise for a total received to date of Four Million Dollars ($4,000,000). An additional One Million Dollars ($1,000,000) of the Purchase Option remains for exercise at the investor's discretion pursuant to the terms and conditions of the subscription agreement of the Offering (“Subscription Agreement”). It is anticipated the remaining One Million Dollars ($1,000,000) of the Purchase Option will be received by the Company on or before June 26, 2025.

PETVIVO HOLDINGS, INC. ANNOUNCES INVESTOR EXERCISE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes.

PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

See News Rankings

Charts implemented using Lightweight Charts™